Literature DB >> 10493085

Paroxetine in social anxiety disorder: a randomized placebo-controlled study.

C Allgulander1.   

Abstract

OBJECTIVE: The aim of this study was to evaluate the utility of paroxetine treatment in social anxiety disorder.
METHOD: Previously undiagnosed and untreated subjects with social anxiety disorder (generalized social phobia) were selected from among responders to a newspaper advertisement. They were randomized to double-blind treatment with paroxetine 20-50 mg daily or placebo for 3 months. Outcome measures were self-rated social anxiety and avoidance behaviour, and clinician-rated global assessment of improvement.
RESULTS: Significant differences in efficacy between treatments (intent-to-treat analysis: 44 subjects on paroxetine and 48 subjects on placebo) were noted after 4-6 weeks, increasing through the treatment period in the paroxetine group. Nine subjects on paroxetine and 3 subjects on placebo discontinued the treatment due to adverse events. Sexual side-effects were noted by 18 subjects on paroxetine and 4 subjects on placebo.
CONCLUSION: Paroxetine was effective in alleviating symptoms and avoidance behaviour in social anxiety disorder.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10493085     DOI: 10.1111/j.1600-0447.1999.tb10845.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  16 in total

1.  Second-generation antidepressants in social anxiety disorder: meta-analysis of controlled clinical trials.

Authors:  Gabriela Bezerra de Menezes; Evandro Silva Freire Coutinho; Leonardo F Fontenelle; Paula Vigne; Ivan Figueira; Márcio Versiani
Journal:  Psychopharmacology (Berl)       Date:  2010-12-22       Impact factor: 4.530

Review 2.  Social anxiety disorder : current treatment recommendations.

Authors:  Jacqueline E Muller; Liezl Koen; Soraya Seedat; Dan J Stein
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 3.  Efficacy and tolerability of second-generation antidepressants in social anxiety disorder.

Authors:  Richard A Hansen; Bradley N Gaynes; Gerald Gartlehner; Charity G Moore; Ruchi Tiwari; Kathleen N Lohr
Journal:  Int Clin Psychopharmacol       Date:  2008-05       Impact factor: 1.659

4.  Refractory social anxiety disorder.

Authors:  Michael Van Ameringen; Beth Patterson
Journal:  J Psychiatry Neurosci       Date:  2017-01       Impact factor: 6.186

5.  INFLUENCE OF STUDY DESIGN ON TREATMENT RESPONSE IN ANXIETY DISORDER CLINICAL TRIALS.

Authors:  Bret R Rutherford; Veronika S Bailey; Franklin R Schneier; Emily Pott; Patrick J Brown; Steven P Roose
Journal:  Depress Anxiety       Date:  2015-10-05       Impact factor: 6.505

6.  Clinical presentation and pharmacotherapy response in social anxiety disorder: The effect of etiological beliefs.

Authors:  Jonah N Cohen; Carrie M Potter; Deborah A G Drabick; Carlos Blanco; Franklin R Schneier; Michael R Liebowitz; Richard G Heimberg
Journal:  Psychiatry Res       Date:  2015-04-16       Impact factor: 3.222

Review 7.  The neurobiology of social phobia: from pharmacotherapy to brain imaging.

Authors:  M Van Ameringen; C Mancini; P Farvolden; J Oakman
Journal:  Curr Psychiatry Rep       Date:  2000-08       Impact factor: 5.285

Review 8.  Spotlight on paroxetine in psychiatric disorders in adults.

Authors:  Antona J Wagstaff; Susan M Cheer; Anna J Matheson; Douglas Ormrod; Karen L Goa
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 9.  Paroxetine: an update of its use in psychiatric disorders in adults.

Authors:  Antona J Wagstaff; Susan M Cheer; Anna J Matheson; Douglas Ormrod; Karen L Goa
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 10.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.